Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder

  • Authors:
    • Katsuya Naruse
    • Yoshiaki Yamada
    • Kogenta Nakamura
    • Shigeyuki Aoki
    • Tomohiro Taki
    • Kenji Zennami
    • Remi Katsuda
    • Masahito Watanabe
    • Genya Nishikawa
    • Youko Itoh
    • Kenji Mitsui
    • Hatsuki Hibi
    • Nobuaki Honda
  • View Affiliations

  • Published online on: June 1, 2010     https://doi.org/10.3892/or_00000798
  • Pages: 1577-1583
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Expression of HER-2 and COX-2 was determined to assess the potential of molecular-targeted therapy against human epidermal growth factor receptor-2 (HER-2) and cyclooxygenase-2 (COX-2) for the treatment of invasive bladder cancer. The subjects were 46 patients who attended Aichi Medical University Hospital between January 2001 and August 2008, underwent total cystectomy with a diagnosis of M0 bladder cancer, and received a pathological diagnosis of invasive transitional cell carcinoma of the urinary bladder (pT2-pT4). Expression of HER-2 and COX-2 was determined by immunohistochemical staining, and the results were interpreted by two pathologists by classifying HER-2 expression into four grades, and considering COX-2 positive when 10% or more of the tumor cells were stained. In HER-2 immunostaining, 10 subjects (21.7%) were positive, all of whom had a Grade 3 tumor. Staging classification identified 2 subjects (2/22, 9.1%) with pT2 stage, 3 (3/16, 18.8%) pT3 stage, and 5 (5/8, 62.5%) pT4 stage. There was a correlation between HER-2 positivity and tumor stage (P=0.007). Lymph node metastasis was detected in 13 subjects, 3 of them (3/8, 37.5%) with pN2 metastasis were HER-2 positive. The 5-year cause-specific survival rate was 51.4% for HER-2-positive subjects and 83.4% for HER-2-negative subjects. The outcome was poorer in HER-2-positive subjects, but the difference in survival rate was not statistically significant (P=0.218). In COX-2 immunostaining, 27 subjects (58.7%) were found to be positive. Three (3/4, 75.0%) showed a Grade 2 tumor and 24 (24/42, 57.1%) a Grade 3 tumor. Staging classification identified 13 subjects (13/22, 59.1%) with pT2 stage, 9 (9/16, 56.3%) pT3 stage, and 5 (5/8, 62.5%) pT4 stage. There was no correlation between COX-2 positivity and tumor grade or stage (P=0.488 and 0.089, respectively). Classification by the extent of lymph node metastasis revealed that 6 subjects (6/8, 75.0%) with pN2 were COX-2 positive. There was a correlation between COX-2 positivity and the extent (pN1 or pN2) of lymph node metastasis (P=0.008). The 5-year cause-specific survival rate was 84.0% for COX-2-positive subjects and 71.7% for COX-2-negative subjects. However, the difference in survival rate was not significant (P=0.407). Seven subjects (7/46, 15.2%) were positive for both HER-2 and COX-2, and there was no statistically significant correlation between the status of HER-2 expression and that of COX-2 expression (P=0.2195). The present study failed to show any association between HER-2 or COX-2 positivity and outcome in subjects with invasive bladder cancer. However, HER-2-positive subjects tended to have a poorer outcome. This finding suggests that molecular-targeted therapy against HER-2 could be an effective therapy. Further studies involving a larger number of subjects are required.

Related Articles

Journal Cover

June 2010
Volume 23 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Naruse K, Yamada Y, Nakamura K, Aoki S, Taki T, Zennami K, Katsuda R, Watanabe M, Nishikawa G, Itoh Y, Itoh Y, et al: Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder . Oncol Rep 23: 1577-1583, 2010.
APA
Naruse, K., Yamada, Y., Nakamura, K., Aoki, S., Taki, T., Zennami, K. ... Honda, N. (2010). Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder . Oncology Reports, 23, 1577-1583. https://doi.org/10.3892/or_00000798
MLA
Naruse, K., Yamada, Y., Nakamura, K., Aoki, S., Taki, T., Zennami, K., Katsuda, R., Watanabe, M., Nishikawa, G., Itoh, Y., Mitsui, K., Hibi, H., Honda, N."Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder ". Oncology Reports 23.6 (2010): 1577-1583.
Chicago
Naruse, K., Yamada, Y., Nakamura, K., Aoki, S., Taki, T., Zennami, K., Katsuda, R., Watanabe, M., Nishikawa, G., Itoh, Y., Mitsui, K., Hibi, H., Honda, N."Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder ". Oncology Reports 23, no. 6 (2010): 1577-1583. https://doi.org/10.3892/or_00000798